Nymox delisting from Nasdaq

Nymox received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the company’s shares will be suspended from trading on Nasdaq at the open of business on July 7. Nymox shares will be moved to the OTC market. Nymox is in the process of submitting applications for the approval to market the company’s first in class drug Nymozarfex to treat the symptoms of benign prostatic hyperplasia. Nymozarfex was submitted to the Danish authorities in December 2022 and the application is currently undergoing review. Another submission for approval in another jurisdiction is expected to be submitted in the near future.